Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442)

• Status: Completed
• Trial end date: 2012-05-01

Summary

The purpose of this study is to evaluate the response of the tumor to the treatment regimen that will be used in this study. This study will also test the safety of cetuximab (C225), given with chemotherapy and radiation therapy. We also want to see what effects (good and bad) cetuximab, chemotherapy, and radiation therapy have head & neck cancer.

C225 has been designed to stop the growth of the tumor by blocking certain chemical pathways that lead to tumor cell growth. In prior studies with head & neck cancer patients, C225 has delayed tumor growth and provided relief of symptoms in some patients.

• Phase: Phase 2

Details

• Lead Sponsor: Department of Radiation Oncology; University of Maryland, Baltimore
• Collaborator: Bristol-Myers Squibb
• Treatments: Albumin-Bound Paclitaxel; Carboplatin; Cetuximab; Paclitaxel